• Adult Immunization
  • Hepatology
  • Pediatric Immunization
  • Screening
  • Psychiatry
  • Allergy
  • Women's Health
  • Cardiology
  • Pediatrics
  • Dermatology
  • Endocrinology
  • Pain Management
  • Gastroenterology
  • Geriatrics
  • Infectious Disease
  • Obesity Medicine
  • Rheumatology
  • Oncology
  • Nephrology
  • Neurology
  • Pulmonology

Basal Cell Carcinoma on Arm of a 57-Year-Old Man

News
Article

A small punch biopsy showed basal cell carcinoma with focal hypermelanosis. The underlying erythema and punctuate superficial dark black pigmentation strongly suggested a dysplastic nevus or even a melanoma.

A 57-year-old man discovered a relatively small (1 cm), pigmented nodule of uncertain duration on his left arm during a cutaneous self-examination. The patient had a previous skin cancer.

Key point: The lesion displays an underlying erythema as well as punctuate superficial dark black pigmentation. While this strongly suggests a dysplastic nevus or even a melanoma, pigmented basal cell carcinoma can appear in this manner. A small punch biopsy disclosed basal cell carcinoma with focal hypermelanosis.

Treatment: The lesion was modestly sized and located on a low-risk skin region. Simple excision (with 5-mm borders) and primary closure was performed.

Note: The different diagnostic possibilities can be precise clinical mimics. Biopsy whenever doubt exists regarding the exact diagnosis.

Related Content
FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis / Image credit: ©InfiniteStudio/AdobeStock

FDA Grants Fast Track Designation to Rezpegaldesleukin for Atopic Dermatitis

Sydney Jennings
February 10th 2025
Article

Rezpegaldesleukin targets the IL-2 receptor complex to stimulate regulatory T cells, aiming to restore immune balance in people with atopic dermatitis.

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Atopic Dermatitis First, Now Onto Asthma for Enveda's Oral Small Molecule Anti-inflammatory Candidate

Grace Halsey
February 7th 2025
Article

The investigational molecule with “JAK-inhibitor-like efficacy and IL4/IL13-like safety,” was cleared in Q4 2024 by the FDA for an IND application, the company said.

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Dupilumab Drug Survival Rates Superior to Those for Upadacitinib and Tralokinumab in Atopic Dermatitis: Large-Scale, Real-World Data

Grace Halsey
February 7th 2025
Article

A first large-scale comparison of length of treatment with advanced AD therapies also identified reasons for discontinuation and examined prior use of biologics and JAK inhibitors.

Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use / image Eric Simpson, MD, MRC, Oregon Health & Science University

Atopic Dermatitis Update: Roflumilast 0.15% Cream Shows Long-Term Safety and Efficacy Plus Benefit with Proactive Use

Grace Halsey
February 5th 2025
Article

Improvement in AD signs and symptoms continued through 56 weeks of treatment with the PDE4 inhibitor including when used just twice weekly as prophylaxis.

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose / image credit: ©New Africa/AdobeStock

Study Identifies Key Symptoms of Topical Steroid Withdrawal: Daily Dose

Sydney Jennings
February 5th 2025
Article

Your daily dose of the clinical news you may have missed.

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial / image credit Sonja Molin, MD Queen’s University

Delgocitinib Effective in Adolescents with CHE in Phase 3 DELTA TEEN Trial

Grace Halsey
February 4th 2025
Article

With no FDA-approved treatments for moderate-to-severe chronic hand eczema in the teen population, the late-stage topline data are very promising.

© 2025 MJH Life Sciences

All rights reserved.